News

Filter

Current filters:

BiotechnologyAnti-virals

1 to 9 of 230 results

NICE draft guidance backs Gilead’s Harvoni for treating chronic hepatitis C

NICE draft guidance backs Gilead’s Harvoni for treating chronic hepatitis C

03-03-2015

The National Institute for Health and Care Excellence (NICE), the medicines cost watchdog for England,…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationUK

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

02-03-2015

The USA’s National Institute of Allergy and Infectious Diseases has launched a clinical trial with…

Anti-viralsBiotechnologyLiberiaMapp BiopharmaceuticalResearchZMapp

Mylan to distribute Sovaldi and Harvoni in India

23-02-2015

US generics major Mylan said today that its Indian subsidiary has entered into an agreement with Gilead…

Anti-viralsBiotechnologyGileadHarvoniIndiaMarkets & MarketingMylanSovaldi

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

04-02-2015

US biotech firm Gilead Sciences posted fourth-quarter and full-year financial results after markets closed…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldi

Chimerix to drop development of brincidofovir for Ebola

Chimerix to drop development of brincidofovir for Ebola

02-02-2015

US antiviral biopharma company Chimerix says that, after discussion with the US Food and Drug Administration,…

Anti-viralsBiotechnologybrincidofovirChimerixResearchTropical diseasesUSA

Valneva grants license to Immune Targeting Systems for the development of hepatitis B vaccine

Valneva grants license to Immune Targeting Systems for the development of hepatitis B vaccine

29-01-2015

France-based biotech firm Valneva and UK company Immune Targeting Systems (ITS) have signed an exclusive…

Anti-viralsBiotechnologyGlobalImmune Targeting SystemsLicensingValneva

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

16-01-2015

In final draft guidance issued today, England health costs watchdog the National Institute for Health…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioPricingRegulationSovaldiUK

1 to 9 of 230 results

Back to top